StocksMedium•12 November 2026•
1 min read
Revolution Medicines RASONQUE Sales Hit $197.6M in First Five Weeks
Key Facts
1Revolution Medicines generated $197.6M in RASONQUE sales within five weeks of FDA approval.
2The drug has reached over 5,000 unique U.S. patients with broad reimbursement coverage.
3The company's valuation stands at 63x forward sales, reflecting high investor expectations.
Revolution Medicines generated $197.6 million in RASONQUE sales within just five weeks of receiving FDA approval. Seeking Alpha reported that the drug has already reached over 5,000 unique patients in the United States, supported by broad reimbursement coverage as the company successfully transitions into commercial operations.
The company's valuation currently stands at 63x forward sales, reflecting high investor expectations for future growth. Shares of Revolution Medicines, trading under the ticker RVMD, closed at $180.7 on November 11, 2026, after reaching an intraday high of $193.35.